<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03796975</url>
  </required_header>
  <id_info>
    <org_study_id>KY20172053-1</org_study_id>
    <nct_id>NCT03796975</nct_id>
  </id_info>
  <brief_title>Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease：an Multicenter，Randomized, Double-blind, Parallel- Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi Aerospace Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genertec Universal Xi'an Aero-Engine hospital (Xi' an) Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi'an Gaoxin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang'An Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yan'an people's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shangluo Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an multicenter, randomized, double-blind, parallel-controlled study to evaluated the&#xD;
      efficacy of pioglitazone hydrochloride and metformin hydrochloride tablets on the patients&#xD;
      with newly diagnosed type 2 diabetes mellitus combined with non-alcoholic fatty liver&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Taking metformin monotherapy as a control, we evaluated the efficacy of pioglitazone&#xD;
      hydrochloride and metformin hydrochloride tablets on hepatic fat ultrasound and liver enzyme&#xD;
      levels, and observed whether the drug can improve fatty liver in patients with newly&#xD;
      diagnosed type 2 diabetes combined with non-alcoholic fatty liver disease. This is an&#xD;
      multicenter, randomized, double-blind, parallel-controlled study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2018</start_date>
  <completion_date type="Actual">November 20, 2019</completion_date>
  <primary_completion_date type="Actual">April 28, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decreased of liver fat content of fatty liver after 24 weeks treatment as assessed by B-ultrasound</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Change from baseline liver fat content to up to 24 weeks after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of B-cell function after 24 weeks treatment as assessed by homeostasis model assessment of insulin resistance index</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Change from baseline B-cell function to up to 24 weeks after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of liver enzyme after 24 weeks treatment as assessed by blood test</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Change from baseline liver enzyme to up to 24 weeks after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decreased of HbA1c after 24 weeks treatment as assessed by blood test</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Change from baseline HbA1c to up to 24 weeks after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased of fasting blood glucose after 24 weeks treatment as assessed by blood test</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Change from baseline fasting blood glucose to up to 24 weeks after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of weight and waistline after 24 weeks treatment as assessed by standard measurement</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Change from baseline weight and waistline to up to 24 weeks after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Efficacy</condition>
  <arm_group>
    <arm_group_label>Combination of Pioglitazone and Metformin Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosage form: tablet; dosage:15mg/500mg; frequency: the dose in week 1 is 15mg/500mg, once a day, increased to 15mg/500mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin Hydrochloride Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dosage form: tablet; dosage: 850mg; frequency: the dose in week 1 is 850mg, once a day, increased to 850mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of Pioglitazone and Metformin Tablets</intervention_name>
    <description>15mg/500mg, oral, 2/day</description>
    <arm_group_label>Combination of Pioglitazone and Metformin Tablets</arm_group_label>
    <other_name>ka shuang ping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride Tablets</intervention_name>
    <description>Oral metformin 850mg, 2/day in the control group</description>
    <arm_group_label>Metformin Hydrochloride Tablets</arm_group_label>
    <other_name>ge hua zhi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. To meet the new diagnosed type 2 diabetes patients, never received oral hypoglycemic&#xD;
             drugs or insulin therapy;&#xD;
&#xD;
          2. In accordance with the nonalcoholic fatty liver (NAFLD) criteria for the diagnosis of&#xD;
             patients.&#xD;
&#xD;
          3. the level of HbA1c was 7 -10.0%;&#xD;
&#xD;
          4. age 18-70, body mass index 21-35kg/m2;&#xD;
&#xD;
          5. the subjects informed consent and signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. type 1 diabetes or secondary diabetes;&#xD;
&#xD;
          2. suffering from other liver diseases, such as hepatitis, self - free liver, etc.&#xD;
&#xD;
          3. abnormal thyroid function (in the active period), or the need for long-term oral and&#xD;
             intravenous glucocorticoids to treat patients;&#xD;
&#xD;
          4. patients with severe renal dysfunction or renal disease (eGFR&lt;60);&#xD;
&#xD;
          5. in those with abnormal liver function, Alanine transaminase(ALT) or Aspartate&#xD;
             transaminase(AST) was more than 3 times the normal upper limit.&#xD;
&#xD;
          6. people with serious gastrointestinal diseases such as peptic ulcers and chronic&#xD;
             diarrhea;&#xD;
&#xD;
          7. patients with severe cardiopulmonary disease, cerebrovascular disease or stents;&#xD;
&#xD;
          8. hemopoietic system diseases such as serious primary diseases, hemoglobin &lt; 100g/L or&#xD;
             need regular transfusion treatment;&#xD;
&#xD;
          9. pregnant, breast-feeding, women of childbearing age who are unwilling to contraception&#xD;
             during the study period;&#xD;
&#xD;
         10. chronic cardiac insufficiency, the classification of heart function III level and&#xD;
             above;&#xD;
&#xD;
         11. uncontrolled malignant tumor, and the history of bladder cancer.&#xD;
&#xD;
         12. acute complications of diabetes;&#xD;
&#xD;
         13. the use of other drugs for diabetes and liver disease;&#xD;
&#xD;
         14. patients who had participated in other clinical studies within three months;&#xD;
&#xD;
         15. people who have known allergies to this kind of drugs are known.&#xD;
&#xD;
         16. it is impossible to guarantee the effect or the safety judgment of the drug or the&#xD;
             person who is unable to cooperate with the mental illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiuhe Ph.D Ji, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology,Xi jing Hospital,Fourth Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hospital, Fourth Military Medical university</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2019</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Non-alcoholic Fatty Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

